Parkman Healthcare Partners LLC Surface Oncology, Inc. Transaction History

Parkman Healthcare Partners LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.42 - $3.15 $132,870 - $294,748	-93,571 Reduced 44.74%	115,577 $190,000
Q1 2022 May 13, 2022	SELL	$2.65 - $5.08 $131,848 - $252,750	-49,754 Reduced 19.22%	209,148 $615,000
Q4 2021 Feb 11, 2022	BUY	$4.73 - $7.9 $50,303 - $84,016	10,635 Added 4.28%	258,902 $1.24 Million
Q3 2021 Nov 12, 2021	BUY	$5.16 - $7.98 $103,200 - $159,600	20,000 Added 8.76%	248,267 $1.88 Million
Q2 2021 Aug 13, 2021	SELL	$6.45 - $9.09 $154,651 - $217,950	-23,977 Reduced 9.51%	228,267 $1.7 Million
Q1 2021 May 14, 2021	BUY	$7.25 - $13.82 $554,277 - $1.06 Million	76,452 Added 43.49%	252,244 $1.97 Million
Q4 2020 Feb 12, 2021	SELL	$6.87 - $10.48 $166,439 - $253,898	-24,227 Reduced 12.11%	175,792 $1.62 Million
Q3 2020 Nov 13, 2020	BUY	$5.06 - $7.23 $379,596 - $542,387	75,019 Added 60.02%	200,019 $1.38 Million
Q2 2020 Aug 13, 2020	BUY	$1.57 - $6.56 $196,250 - $820,000	125,000 New	125,000 $820,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.